Background: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remains debated.
a long-term basis. These drugs have demonstrated a response rate greater than 50% for CLE, and their use has been expanded to various other inflammatory conditions. 1 The stepwise algorithm involves an initial trial of HCQ followed by the addition of Q if HCQ monotherapy fails. CQ is ultimately added, often also in combination with Q, if HCQ and Q combination therapy (HCQ-Q) fails. 2 Recently there has been renewed interest in Q. This drug has synergistic efficacy when given as part of an antimalarial combination and has demonstrated therapeutic promise for recalcitrant disease. 3, 4 Emerging evidence suggests that this effect may due to the fact that Q has a distinct mechanism compared with its counterparts involving the downregulation of toll-like receptor 3 (TLR-3), TLR-4, and TLR-8 responses. 5, 6 Q has been compounded since the early 1990s, when production was discontinued by Sanofi-Winthrop. 7 In March 2016, the Pharmacy Compounding Advisory Committee examined Q as part of its regular monitoring of compounded drugs that is mandated by the Drug Quality and Security Act (2013).
After weighing disparate recommendations from infectious disease, rheumatology, and reproductive health specialists, the Office of New Drugs voted to discontinue compounding of this medication for all indications. It further recommended that for patients who are intolerant or unresponsive to approved alternate therapies, Q could be prescribed through an investigational new drug application. This would require institutional review board approval and patient consent. 8 If approved, these regulatory requirements may severely restrict availability of Q for all uses. The concerns of the US Food and Drug Administration were based primarily on reports during World War II of Q-associated aplastic anemia and hepatitis, which occurred at dosages exceeding the standard dose of 100 mg/d that is typically prescribed for rheumatic skin disease.
According to these recent Pharmacy Compounding Advisory Committee proceedings, there remains a lack of consensus on the risk for toxicities associated with Q and other drugs in its class. Most commonly, Q causes transient gastrointestinal (GI) upset, yellow skin discoloration, and headache. 9 Retinal toxicity, the most feared complication associated with HCQ or CQ therapy, is not known to occur with Q. The retinopathy risk is greater with CQ, which is why this drug is typically reserved for patients refractory to HCQ-Q treatment. 10 Other serious toxicities associated with HCQ and CQ include cardiomyopathy, 11 myopathy, 12 and ototoxicity. 13 Certain reversible but more common adverse effects include GI discomfort and mucocutaneous blue-black dyspigmentation. 14 The body of clinical experience with Q reflects its efficacy and safety, particularly for patients with recalcitrant disease and those at risk for antimalarial-induced retinopathy. Given that Q is used frequently, it is critical to investigate the risk for toxicities associated with this drug relative to that associated with others in its class. 15 Additionally, because Q is typically given in combination with either HCQ or CQ, it is also necessary to determine whether combination therapy affects the risk for development of antimalarialinduced toxicities. In this study, we have investigated the incidence over time and the risks of toxicities associated with HCQ, CQ, and Q monotherapies, as well as those associated with HCQ-Q and CQ-Q in patients with rheumatic skin diseases.
METHODS

Subject selection
In this retrospective cohort study, patients were selected from 2 longitudinal databases on CLE and dermatomyositis (DM) that have been ongoing since January 2007 and January 2008, respectively. Both databases were initiated by the principle investigator's research team and consist of patients seen at the outpatient autoimmune skin disease clinic of the Hospital of the University of Pennsylvania. Patients included in this study have been enrolled in the databases since their creation and were accessed for this study until August 2016. Those without a history of antimalarial treatment were excluded. Additionally, patients for whom there are no records following initiation of antimalarial therapy were excluded because the ability to tolerate the medication(s) cannot be determined for this subset (Fig 1) Antimalarials were generally well tolerated and had similar risk profiles. Risk for retinopathy seems to be lowest for quinacrine, then hydroxychloroquine, and highest for chloroquine.
and have a clinicohistopathologic diagnosis of either CLE or DM (Table I) .
Data collection
Information in the CLE and DM databases is collected prospectively when enrolled patients attend regularly scheduled clinic visits at the Hospital of the University of Pennsylvania. In the medication history of the database records, a toxicity is attributed to a drug if it is clinically characteristic of a side effect known to be associated with that medication. This determination may be based on a combination of the patient's symptoms, physical examination findings, temporal association between treatment initiation or discontinuation, and appearance or resolution of toxicity, respectively, as well as on the results of diagnostic testing reports. In the case of antimalarial-induced retinopathy, affected patients had either subjective complaints of visual deficits or ophthalmology reports including results of the Humphrey visual field test, optic coherence tomography, or multifocal electroretinography providing evidence of the drug's toxicity.
For this study, database records were reviewed to extract details regarding antimalarial drug use and history of toxicities related to treatment. The types of antimalarial medications, the dates of initiation and discontinuation of therapy, the types of antimalarialinduced toxicities that occurred, and the initial dates of these episodes were collected. For a given date, if only the month of a year or simply the year was available, then the first day of that particular month or of the year was recorded, respectively. Similarly, if only a particular season was available for a certain date (for example, summer 2010), then the first day of the season was recorded.
Statistical analysis
To analyze the relationship between toxicities and antimalarial treatment over time, a treatment course was defined as the duration of a monotherapy or combination of antimalarial drugs. The start of the course was designated as the date of initiation of therapy, and the end was the discontinuation of therapy for any reason. A course was considered continuous if it included no more than 1 month of a missed dose, given the lengthy elimination half-lives of antimalarials. 10 The 5 different treatment courses included HCQ monotherapy, CQ monotherapy, Q monotherapy, HCQ-Q, and CQ-Q. No patients had a HCQ-CQ course because these 2 drugs are never combined on account of their additive risk for development of retinal toxicity. Patients often had a history of multiple types of treatment courses because therapy is typically modulated over time (Table II) . In all, 41.7% of patients (n = 222) began with HCQ and later switched to either HCQ-Q or Q. Additionally, 16.9% of patients (n = 90) initially took HCQ or Q monotherapy or HCQ-Q and then switched to either CQ or CQ-Q. Patients recorded as having started with antimalarial combinations different from HCQ monotherapy usually had other regimens before their enrollment in the CLE and DM databases. The absolute incidences of toxicities were calculated, and the incidences of the 5 most common toxicities per person-year of each antimalarial treatment course were determined. A given toxicity was attributed to a treatment course as long as it occurred during a treatment course or within 2 weeks of discontinuation of the corresponding antimalarial regimen. For the 5 most common toxicities, the time to event was defined as the time between treatment initiation and toxicity occurrence. A subject was censored if toxicity did not occur by the end of the follow-up period. The time to each type of toxicity during treatment with different antimalarial combinations was summarized using Kaplan-Meir survival curves. Then, for each toxicity type, the hazard ratios (HRs) comparing the different antimalarials with HCQ were estimated by using the Cox proportional hazard model adjusted for sex, race (white vs nonwhite), smoking status (never-smoker vs smoker), and age at baseline visit. To compare the HRs of each toxicity between HCQ and each other treatment course, Bonferroni-adjusted significance levels were used according to the number of comparisons conducted within each Cox model. All statistical analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary, NC).
RESULTS
The most common toxicities associated with antimalarials included cutaneous eruption (n = 61), GI upset (n = 38), mucocutaneous dyspigmentation (Table III) . The 2 patients with only subjective complaints of decreased visual acuity were excluded from additional statistical analysis, and only those with objective evidence of ocular toxicity based on standard ophthalmologic examination findings (eg, a bull's eye pattern of damage on optic coherence tomography) (n = 15) were further analyzed. The incidences of these toxicities per person-year of treatment with the 5 different combinations of antimalarials were 0 to 0.073 for cutaneous eruption, 0.013 to 0.057 for GI upset, 0 to 0.476 for mucocutaneous dyspigmentation, 0 to 0.045 for neurologic toxicities, and 0 to 0.004 for retinopathy (Supplemental Table I ; available at http://www.jaad.org).
Compared with the risk for cutaneous eruption with HCQ monotherapy, that for cutaneous eruption was significantly lower with HCQ-Q (HR, 0.231; 95% confidence interval [CI], 0.07-0.82; P = .0056). The hazard of cutaneous eruption with other antimalarial combinations was not significantly different from that of HCQ monotherapy. Additionally, the hazard of GI upset during HCQ-Q was much smaller than that during HCQ monotherapy (HR, 0.229), though the difference was just close to being statistically significant (P = .0157). Compared with the hazards of retinopathy with HCQ, the hazards of retinopathy were significantly greater with both CQ (HR, 30.349; (Table IV) . A post hoc analysis was performed to analyze whether patients who developed toxicity during HCQ or CQ monotherapy were less likely to later receive HCQ-Q or CQ-Q, respectively. A lower percentage of those with certain toxicities during treatment with HCQ later received HCQ-Q as compared with those without toxicity to HCQ (11.1% with cutaneous eruption vs 37.7% with no cutaneous eruption, 22.2% with GI upset vs 55.7% with no GI upset, 27.3% with neurologic toxicities vs 36.2% with no neurologic toxicities, and 0% with retinopathy vs 36.2% with no retinopathy). HCQ-Q was later given to a greater percentage of those with dyspigmentation (50%) during treatment with HCQ versus those without dyspigmentation (35.5%). overdose. # Two of these patients reported only subjective complaints of visual deficits; the remainder had evidence of antimalarial induced retinal toxicity based on visual field testing. **Subjective complaints of arthralgia and myalgia. yy Seen in 1 patient after 1 month of hydroxychloroquine, in 1 patient after 2 years of hydroxychloroquine plus quinocrine; and in 2 patients 3 months after quinocrine was added to long-term (25 years and 7 years) hydroxychloroquine monotherapy. zz One case of arrhythmia during chloroquine therapy and 1 case of palpitations during hydroxychloroquine therapy.
xx Self-limited chest tightness and dyspnea for 20 minutes after hydroxychloroquine had been taken; whether it was due to antimalarial medication is unclear, but hydroxychloroquine was discontinued.
kk Pancytopenia in the setting of evolving myelodysplastic syndrome; whether it was due to antimalarial medication is unclear. {{ Lethargy and weakness.
None of those with GI upset and ophthalmic toxicity to CQ later received CQ-Q. Cutaneous eruption, dyspigmentation, and neurologic toxicities did not occur with CQ.
DISCUSSION
More than 90% of our patients had a history of HCQ therapy, and nearly half (42.9%) had a history of receiving HCQ-Q. Only approximately 20% of patients had a history of receiving CQ either as monotherapy (11.1%) or in combination with Q (10.2%). More than half of the patients had a history of taking Q, usually in combination with HCQ or CQ, but also as monotherapy (11.8%). This pattern is consistent with the stepwise algorithm for antimalarials in rheumatic skin disease and also illustrates the substantial proportion of patients reliant on a combination regimen.
Consistent with prior literature, the most prevalent toxicities in our sample included cutaneous eruption, GI upset, mucocutaneous dyspigmentation, neurologic toxicities (including primarily headache and dizziness), and retinopathy. The incidences of retinopathy per person-year of the various antimalarial treatment combinations were relatively lower than those of the other toxicities. This may be due to the time-dependent nature of retinal toxicity, the risk for development of which is less than 1% after 5 years but rises to 20% after 20 years of antimalarial use. 16, 17 Importantly, although retinopathy may be rarer than other toxicities, it is often irreversible and more serious. Conversely, cutaneous eruption had the highest incidence per person-year of treatment with HCQ. This may reflect the shorter period that typically elapses between initiation of the drug and development of a hypersensitivity skin reaction. Relative to HCQ, HCQ-Q was associated with significantly lower risk for cutaneous eruption. Additionally, consistent with prior evidence on the greater association of retinopathy with CQ than with HCQ, we found an increased risk for retinopathy with CQ and CQ-Q relative to that associated with HCQ.
Our post hoc analysis was intended to determine whether our findings represent a protective benefit of Q or the selection of individuals able to tolerate HCQ in the cohort of patients with a history of HCQ-Q. We indeed found that compared with patients with an unremarkable course of HCQ therapy, those who experienced cutaneous eruption, GI upset, neurologic toxicities, and retinopathy during HCQ treatment were less likely to later receive HCQ-Q. Interestingly, this pattern did not apply to dyspigmentation. This may be because dyspigmentation resolves with continued therapy and does not cause bothersome physical symptoms beyond its cosmetic inconvenience. However, this is purely speculative.
Although a protective benefit of Q is unlikely on the basis of our analysis, these findings suggest that combining Q with HCQ or CQ does not increase the risk for toxicity associated with these drugs. Notably, there were no cases of retinal toxicity with Q. Additionally, there were no cases of aplastic anemia or severe hepatitis due to Q. Although these 2 serious adverse effects are the basis of the concern of the US Food and Drug Administration regarding Q, records from World War II indicate that they occurred in only 1 of 500,000 soldiers. Additionally, these toxicities have not been reported at a dose of 100 mg/d. 9, [18] [19] [20] [21] [22] Compared with HCQ, Q was not associated with any significant difference in the risk for any common toxicity (ie, cutaneous eruption, GI upset, dyspigmentation, and neurologic toxicities).
The main limitation of this study is its retrospective nature. We attributed toxicities to the treatment(s) that patients were receiving either at the time or 2 weeks before occurrence of the event. Although this may be suitable for toxicities that occur relatively quickly following initiation of treatment (ie, cutaneous eruption), it is imperfect for retinal toxicity, which is time dependent. Of the 15 patients with retinopathy, 7 developed this deficit toward the end of their initial antimalarial course. The remaining patients developed retinopathy toward the end of a second or third treatment course. In these cases, retinal changes did not develop until 9 months to 20 years (median, 6 years; 95% CI, 2.85-9.35) following initiation of the treatment course to which the toxicity was attributed. Additionally, the most recent screening guidelines for antimalarial retinopathy recommend annual screening after 5 years for patients without major risk factors. 17 Given that all patients receiving HCQ and CQ in our cohort received annual ophthalmic examinations, it is unlikely that retinal changes started during prior treatment courses in this subgroup.
Of the patients in our cohort, 2 (0.38%) presented with subjective complaints of visual blurring after starting to take antimalarials but did not have objective evidence of retinal damage. Future investigations may determine the incidence and risk for antimalarial-induced nonretinal complications, which may currently be under-recognized. 23 Additionally, we did not examine the impact of dosages on the development of toxicities, as most patients were receiving standard antimalarial dosages, which were infrequently altered (eg, 200-400 mg/d of HCQ, 100 mg/d of Q, and 250 mg/d of CQ). Finally, the focus of this study was on established antimalarial toxicities as opposed to the detection of new side effects. Future studies are needed to investigate the impact of cumulative dosages on toxicities and to potentially discover new antimalarial toxicities.
Our study provides evidence that the safety profile of Q is not statistically significantly different from that of HCQ and that Q has an advantage over HCQ and CQ for patients at risk for retinopathy. Adding Q to HCQ or CQ does not increase the risk for toxicities according to our results, and limiting access to Q may leave patients without alternatives to this safe drug. Before making a final decision about the future availability of Q, we must continue examining the true safety risks associated with this important class of medications. CQ, Chloroquine; CQ-Q, chloroquine plus quinacrine; GI, gastrointestinal; HCQ, hydroxychloroquine; HCQ-Q, hydroxychloroquine plus quinacrine; Q, quinacrine.
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